10-Q · May 14, 2026
Cellectar Biosciences, Inc. reported a net loss for Q1 2026, with significant focus on advancing its drug development pipeline amid funding challenges. R&D expenses decreased slightly year-over-year, reflecting…
Earnings analysis · 10-Q
CLRB earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The filing provides no current-quarter income statement, cash-flow, balance-sheet, segment, or EPS figures in the supplied text, so quarter-over-quarter and year-over-year financial trends cannot be assessed. Management…
Read full summary
The filing provides no current-quarter income statement, cash-flow, balance-sheet, segment, or EPS figures in the supplied text, so quarter-over-quarter and year-over-year financial trends cannot be assessed. Management is pursuing an FDA NDA for accelerated approval and a potential EMA conditional marketing approval, but explicitly states that existing cash is insufficient to execute this regulatory strategy. Persistent material weaknesses in internal control through June 30, 2026 and the added regulatory-approval risk materially weaken the outlook.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
NDA Submission Strategy
Management states it plans to submit an NDA to the FDA for accelerated approval of iopofosine I 131 in WM patients who have received two prior lines of therapy, including a BTKi.
-
EMA Approval Pathway
The company is continuing dialogue with the EMA regarding a possible conditional marketing approval submission, following feedback through the EMA scientific advice procedure.
-
Material Control Weaknesses Persist
Disclosure controls and procedures were concluded to be ineffective as of June 30, 2026, due to material weaknesses in internal control over financial reporting that management said existed as of December 31, 2025.
What to watch
-
Insufficient Cash for Regulatory Plan
The company states that existing cash and cash equivalents are not sufficient to execute its regulatory strategy and that additional funds are required before NDA submission and initiation of the proposed confirmatory study.
-
Approval of Iopofosine Not Assured
FDA, EMA, and other regulators may reject or require additional work for the planned NDA or equivalent application; the strategy targets patients who have received two prior lines of therapy, including a BTKi.
-
Financial Reporting Control Deficiencies
Internal-control deficiencies include inaccurate accounting for preferred equity and warrants, stock-based compensation related to restricted stock awards granted in December 2023, and valuation assumptions for preferred warrants. Management said the weaknesses continued through June 30, 2026.
Management's outlook
The 10-Q does not provide quantitative revenue or EPS guidance. Management states that additional funding is a precursor to NDA submission and initiation of the proposed confirmatory study.
Earlier filings 4
10-K · April 30, 2026
Cellectar Biosciences, Inc. reported a narrower loss for Q4 2025, with an actual EPS of -0.53 compared to an estimate of -1.21, reflecting improved operational management or cost controls. The firm continues to leverage…
10-K · March 4, 2026
Cellectar positions itself as a late-stage clinical biotech leveraging a proprietary phospholipid drug-conjugate (PDC/PRC) platform, with iopofosine I-131 as the lead compound showing strong CLOVER WaM Phase 2 results…
10-Q · November 18, 2024
Cellectar reported a three-month net loss of $14,664,719 (net loss per diluted share $0.40) for the quarter ended September 30, 2024. Cash and equity positions materially improved versus December 31, 2023 (cash…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.